Imunon, Inc.
IMNNImunon, Inc. in brief
Imunon, Inc. is a listed company in the Biotechnology industry, based in Lawrenceville, New Jersey, USA. Its market value was $5 M on 30 October 2026, which makes it the 26,819th largest listed company in the world and the 4,393rd largest in the USA on this site. It employs about 20 people and Stacy Lindborg is its chief executive. Its shares trade under the symbol IMNN (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About Imunon, Inc.
The Imunon brand and product names contained in this document are trademarks, registered trademarks or service marks of Imunon, Inc. or its subsidiary in the United States and certain other countries. This document also contains references to trademarks and service marks of other companies that are the property of their respective owners.
Imunon is a clinical-stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the body’s natural mechanisms with the aim to generate safe, effective and durable responses across a broad array of human diseases, constituting a differentiating approach from conventional therapies. Imunon is developing its non-viral DNA technology across its modalities. The first modality, TheraPlas®, is developed for the coding of proteins and cytokines in the treatment of solid tumors where an immunological approach is deemed promising. The second modality, PlaCCine®, is developed for the coding of viral antigens that can elicit a strong immunological response. This technology may represent a promising platform for the development of vaccines in infectious diseases.
From the company's annual report filed with the US SEC: read the report
Imunon, Inc. timeline
- 1996
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 1998
- ✎Renamed Celsion CorpFormerly Cheung Laboratories Inc.
- 2022
- 💰Record revenue of $0 millionFY2022, the highest of the 5 years on record.
- ✎Renamed Imunon, Inc.Formerly Celsion Corp.
Events of Imunon, Inc. from SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #5,580 (Dec 2022) · #5,363 (Jul 2023) · #4,582 (Jan 2024) · #2,378 (Mar 2026) · #4,064 (Aug 2026) · #4,309 (Oct 2026) · #4,395 (Oct 2026)
Key ratios
- P/E ratio
- n/m (loss)
- Price / sales
- —
- Price / book
- 0.8×
- Free cash flow yield
- -263.6%
- Net margin
- —
- Operating margin
- —
- Return on equity
- -205.4%
- Liabilities / assets
- 42.6%
- Net debt
- $-6M
- Revenue growth
- 0.0%
- R&D / revenue
- 2346.0%
- Profit per employee
- $-725 K
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | — | — | $-15M | $-15M | — |
| Dec 2024 | — | — | $-19M | $-19M | — |
| Dec 2023 | — | — | $-21M | $-20M | — |
| Dec 2022 | $1M | 0.0% | $-25M | $-36M | -7180.0% |
| Dec 2021 | $1M | 0.0% | $-21M | $-21M | -4154.0% |
| Dec 2020 | $1M | 0.0% | $-18M | $-21M | -4296.0% |
| Dec 2019 | $1M | 0.0% | $-21M | $-17M | -3370.0% |
| Dec 2018 | $1M | — | $-21M | $-12M | -2376.0% |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $-14M | $0M | $-14M | $-6.83 | — |
| Dec 2024 | $-19M | $0M | $-19M | $-16.94 | — |
| Dec 2023 | $-19M | $0M | $-19M | $-2.16 | — |
| Dec 2022 | $-23M | $0M | $-23M | $-5.03 | — |
| Dec 2021 | $-16M | $0M | $-17M | $-3.83 | — |
| Dec 2020 | $-16M | $0M | $-16M | $-10.08 | — |
| Dec 2019 | $-20M | $0M | $-21M | $-0.77 | — |
| Dec 2018 | $-7M | $0M | $-7M | $-0.68 | — |
Quarterly results
Latest quarter to Sep 2026: revenue —, net income $-4M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.
SEC filings
- Nov 12, 202610-QQuarterly report · period to Sep 2026
- Nov 12, 20268-KCurrent reportResults of operations
- Oct 28, 2026S-1/AIPO registration (amended)
- Oct 27, 2026S-1IPO registration
- Oct 27, 20268-KCurrent reportOther events
- Oct 21, 20268-KCurrent reportMaterial agreement · Regulation FD disclosure
- Sep 29, 20268-KCurrent reportMaterial agreement · Unregistered share sale · Bylaws amended
- Aug 11, 20268-KCurrent reportDirectors or officers changed
- Aug 11, 202610-QQuarterly report · period to Jun 2026
- Aug 11, 20268-KCurrent reportResults of operations
- Jun 30, 20268-KCurrent reportDirectors or officers changed
- Jun 16, 20268-KCurrent reportDirectors or officers changed · Shareholder vote
Official filings of Imunon, Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- —
- Operating income
- $-15 M
- Net income
- $-15 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $12 M
- Total liabilities
- $5 M
- Total equity
- $7 M
As of December-2025
Top 22 institutional investors in Imunon, Inc.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | Armistice Capital, LLC | 270,497 | +125,730 (+86.85%) | 4.17% | $0 M | Nov 16, 2026 |
| 2 | Vanguard Capital Management LLC | 46,967 | 0 (0.00%) | 0.72% | $0 M | Nov 13, 2026 |
| 3 | Geode Capital Management, LLC | 41,104 | +9,475 (+29.96%) | 0.63% | $0 M | Nov 6, 2026 |
| 4 | Nvest Financial, LLC | 26,286 | New | 0.41% | $0 M | Nov 12, 2026 |
| 5 | State Street Corp | 15,831 | New | 0.24% | $0 M | Nov 12, 2026 |
| 6 | Vanguard Fiduciary Trust Co | 13,269 | 0 (0.00%) | 0.20% | $0 M | Nov 13, 2026 |
| 7 | HRT Financial LP | 11,697 | New | 0.18% | $0 M | Nov 13, 2026 |
| 8 | Northern Trust Corp | 10,342 | 0 (0.00%) | 0.16% | $0 M | Nov 16, 2026 |
| 9 | Tower Research Capital LLC (TRC) | 5,596 | +1,644 (+41.60%) | 0.09% | $0 M | Nov 16, 2026 |
| 10 | BlackRock, Inc. | 4,464 | 0 (0.00%) | 0.07% | $0 M | Nov 13, 2026 |
| 11 | Wells Fargo & Company/mn | 3,285 | -57 (-1.71%) | 0.05% | $0 M | Nov 16, 2026 |
| 12 | UBS Group AG | 2,027 | -3,176 (-61.04%) | 0.03% | $0 M | Nov 10, 2026 |
| 13 | Morgan Stanley | 1,503 | -71 (-4.51%) | 0.02% | $0 M | Nov 13, 2026 |
| 14 | SBI Securities Co., Ltd. | 1,027 | 0 (0.00%) | 0.02% | $0 M | Oct 22, 2026 |
| 15 | Citigroup Inc | 922 | New | 0.01% | $0 M | Nov 4, 2026 |
| 16 | Group One Trading LLC | 6 | 0 (0.00%) | 0.00% | $0 M | Nov 10, 2026 |
| 17 | Osaic Holdings, Inc. | 3 | +1 (+50.00%) | 0.00% | $0 M | Nov 12, 2026 |
| 18 | Northwestern Mutual Wealth Management Co | 2 | -1 (-33.33%) | 0.00% | $0 M | Nov 13, 2026 |
| 19 | Royal Bank Of Canada | 1 | 0 (0.00%) | 0.00% | $0 M | Nov 16, 2026 |
| 20 | Steigerwald, Gordon & Koch Inc. | 1 | 0 (0.00%) | 0.00% | $0 M | Nov 12, 2026 |
| 21 | Game Plan Financial Advisors, LLC | 1 | 0 (0.00%) | 0.00% | $0 M | Nov 10, 2026 |
| 22 | GK Wealth Management LLC | 1 | New | 0.00% | $0 M | Oct 9, 2026 |
Mutual funds holding Imunon, Inc.#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc. | 46,967 | $0 M | 0.72% | <0.01% | +191% | Jun 30, 2026 |
| 🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC | 20,413 | $0 M | 0.31% | <0.01% | +19% | May 31, 2026 |
| 🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC | 4,744 | $0 M | 0.07% | <0.01% | +50% | May 31, 2026 |
| 🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC | 1,776 | $0 M | 0.03% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC | 163 | $0 M | <0.01% | <0.01% | no change | May 31, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jun 30, 2026. The 5 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at Imunon, Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Douglas Vincent FallerChief Medical Officer | Grant or award | +1,596 | $0.845 | $1 K | 76,356 | Form 4 |
| filed | Stacy LindborgPresident and CEO, Director | Grant or award | +3,804 | $0.845 | $3 K | 122,581 | Form 4 |
| filed | Michael H. TardugnoExecutive Chairman of Board, Director | Grant or award | +9,969 | $0.845 | $8 K | 128,511 | Form 4 |
| filed | Frederick J. FritzDirector | Grant or award | +13 | $0.845 | $11 | 28,242 | Form 4 |
| filed | Christine A. PellizzariDirector | Grant or award | +13,166 | $0.845 | $11 K | 28,665 | Form 4 |
| filed | James E. DentzerDirector | Grant or award | +13,166 | $0.845 | $11 K | 34,197 | Form 4 |
| filed | Donald P. BraunDirector | Grant or award | +11,746 | $0.845 | $10 K | 33,643 | Form 4 |
| filed | Stacy LindborgPresident and CEO, Director | Grant or award | +2,603 | $1.235 | $3 K | 118,777 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: Imunon, Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Trading halts
- 2025-07-24 23:50 UTC, code T3, resumed 13:00 UTC
- 2025-05-27 13:30 UTC, code LUDP, resumed 13:35 UTC
- 2025-05-23 14:00 UTC, code LUDP, resumed 14:05 UTC
- 2025-05-23 13:42 UTC, code LUDP, resumed 13:47 UTC
- 2025-05-23 13:36 UTC, code LUDP, resumed 13:41 UTC
Fails to deliver
- : 11,909 shares at $0.83
- : 12,794 shares at $0.83
- : 7,933 shares at $0.88
- : 94 shares at $1.07
- : 1 shares at $1.28
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
Imunon, Inc. scorecard#
Passes 2 of the 4 checks that could be worked out. Fiscal year 2026; market cap of Oct 30, 2026.
Valuation1 of 3
- ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
- ✓Price to book below its peers' median0.8×Price to book 0.8× against Biotechnology's median of 2.9×.
- –Price to sales below its peers' medianNo Price to sales on file.
- –Free cash flow yield above 5%No free cash flow yield on file.
- ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
- –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
Growthnot known
- –Revenue grew in the newest yearRevenue of the year before is not on file.
- –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
- –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
- –Earnings per share grew in the newest yearEarnings per share of two years are not on file.
- –Net income higher than five years earlierNet income of five years earlier is not on file.
- –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
Profitabilitynot known
- –Profitable in the newest yearNo net income on file.
- –Profitable in each of the last five yearsFive years of net income are not on file.
- –Operating margin above its peers' medianNo operating margin on file.
- –Return on equity above 15%No return on equity (equity missing or negative).
- –Return on invested capital above 10%No return on invested capital on file.
- –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
Financial healthnot known
- –Short-term assets cover short-term liabilitiesCurrent assets and liabilities are not on file.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- –Cash from operations positive in each of the last three yearsThree years of operating cash flow are not on file.
- –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
Shareholder returns1 of 1
- ✓Pays a dividendYesPaid dividends in fiscal 2026.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- –Share count up no more than 2% in a yearShare counts of two years are not on file.
- –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
- –Free cash flow covers dividends and buybacksCash from operations or capital spending is not on file.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Imunon, Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 | FY 2019to Dec 31, 2019 | FY 2018to Dec 31, 2018 | FY 2017to Dec 31, 2017 | FY 2016to Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||||
| Revenue | — | — | — | 0.50.0%100% | 0.50.0%100% | 0.50.0%100% | 0.50.0%100% | 0.50.0%100% | 0.5—100% | — | |
| Research and development | 7.8−33.2%— | 12+3.1%— | 11−3.8%— | 12+10.5%2347% | 11−6.4%2124% | 11−13.2%2269% | 13+10.1%2613% | 12−9.3%2373% | 13−10.6%2616% | 15—— | |
| General and administrative | 6.9−8.3%— | 7.5−23.1%— | 9.7−28.8%— | 14+25.7%2738% | 11+42.5%2178% | 7.6−4.5%1528% | 8.0−17.5%1600% | 9.7+64.7%1940% | 5.9−9.8%1178% | 6.5—— | |
| Operating expenses | 15−23.4%— | 19−9.0%— | 21−17.3%— | 25+18.2%5084% | 22+13.3%4301% | 19−9.9%3797% | 21−2.3%4213% | 22+13.7%4313% | 19−10.3%3794% | 21—— | |
| Operating income | −15—— | −19—— | −21—— | −25—−4984% | −21—−4201% | −18—−3697% | −21—−4113% | −21—−4213% | −18—−3694% | −21—— | |
| Interest and finance income | — | 0.5−38.0%— | 0.7+44.4%— | 0.5+2670%101% | 0.0−72.7%3.6% | 0.1−85.0%13.3% | 0.4+21.8%88.6% | 0.4r0.3+1297%72.8% | 0.0−16.7%5.2% | 0.0—— | |
| Interest expense and finance costs | — | — | 0.2−96.1%— | 5.0+782%1006% | 0.6−55.9%114% | 1.3—258% | — | — | — | — | |
| Other non-operating income (expense) | 0.2−69.6%— | 0.5+118%— | 0.2—— | −13—−2509% | −1.1—−229% | −4.8−355%−969% | 1.9—379% | −1.2—−247% | −1.9—−387% | −1.4—— | |
| Income before tax | 15−22.0%— | 19r−19—— | −21—— | −37—−7493% | −22—−4431% | −23—−4666% | −19—−3734% | −22—−4460% | −20—−4080% | — | |
| Income tax | — | — | −1.3—— | −1.6—−313% | −1.4—−277% | −1.8—−369% | −1.8—−363% | −10—−2084% | — | — | |
| Net income attributable to shareholders | −14—— | −19—— | −20—— | −36—−7180% | −21—−4154% | −21—−4297% | −17—−3370% | −12—−2377% | −20—−4080% | −22—— | |
| Earnings per share, basic | -6.83—— | -16.94r-1.62—— | -2.16—— | -5.03—— | -3.83—— | -10.08r-0.67—— | -0.77—— | -0.68—— | -2.72—— | -11.89r-0.85—— | |
| Earnings per share, diluted | -6.83—— | -16.94r-1.62—— | -2.16—— | -5.03—— | -3.83—— | -10.08r-0.67—— | -0.77—— | -0.68—— | -2.72—— | -11.89r-0.85—— | |
| Shares, weighted average (basic) | 2.1+93.2%— | 1.1r12−87.9%— | 9.0+26.6%— | 7.1+31.6%— | 5.4—— | — | — | — | — | — | |
| Shares, weighted average (diluted) | 2.1+93.2%— | 1.1r12−87.9%— | 9.0+26.6%— | 7.1+31.6%— | 5.4+155%— | 2.1r32−90.2%— | 22+24.2%— | 18+131%— | 7.6+311%— | 1.9r26—— | |
| Balance sheet | |||||||||||
| Cash and cash equivalents | 8.8+49.5%71.5% | 5.9+0.6%60.4% | 5.8−49.2%26.6% | 11−41.3%26.1% | 20+14.1%26.5% | 17+150%45.7% | 6.9−48.5%18.0% | 13+16.7%28.5% | 11+336%24.1% | 2.6—8.5% | |
| Short-term investments | — | — | 9.8−53.9%44.7% | 21−28.8%48.3% | 30—40.3% | — | 7.9−44.2%20.8% | 14r14+11.7%30.4% | 13r13+658%26.8% | 1.7—5.4% | |
| Other current assets | — | — | — | — | — | — | — | — | — | 0.1—0.4% | |
| Current assets | 11+33.9%87.3% | 8.0−56.1%82.4% | 18−50.4%83.2% | 37r37−29.2%83.6% | 52+176%70.2% | 19+16.0%50.2% | 16−42.3%42.4% | 28+15.7%60.0% | 24+439%51.2% | 4.5—14.6% | |
| Property, plant and equipment | 0.5−2.1%4.3% | 0.5−28.0%5.6% | 0.8+37.1%3.4% | 0.5+14.9%1.2% | 0.5+61.9%0.6% | 0.3−27.3%0.8% | 0.4+120%1.1% | 0.2+5.0%0.4% | 0.2−62.0%0.4% | 0.5—1.5% | |
| Right-of-use (leased) assets | 1.0−11.9%8.0% | 1.1−30.0%11.5% | 1.6+923%7.3% | 0.2−77.4%0.4% | 0.7−34.0%0.9% | 1.0−26.8%2.8% | 1.4+30.1%3.7% | 1.1—2.3% | — | — | |
| Goodwill | — | — | — | — | — | 2.00.0%5.3% | 2.00.0%5.2% | 2.00.0%4.2% | 2.00.0%4.2% | 2.0—6.4% | |
| Other intangible assets | — | — | — | — | — | 0.1−66.7%0.3% | 0.3−40.0%0.9% | 0.6−28.6%1.2% | 0.8−22.2%1.7% | 1.0—3.3% | |
| Non-current assets | — | — | — | — | — | — | 22+16.7%56.5% | 19−19.5%39.6% | 23−11.0%48.5% | 26—83.9% | |
| Total assets | 12+26.5%100% | 9.7−55.7%100% | 22−50.2%100% | 44−40.6%100% | 74+97.3%100% | 38−2.0%100% | 38−18.3%100% | 47−1.4%100% | 48+54.0%100% | 31—100% | |
| Accounts payable | 1.4+7.1%11.3% | 1.3−63.0%13.4% | 3.5−2.0%16.0% | 3.6+40.8%8.2% | 2.5+13.5%3.4% | 2.2−21.6%6.0% | 2.9−5.2%7.5% | 3.0−11.6%6.4% | 3.4+18.7%7.2% | 2.9—9.3% | |
| Current liabilities | 4.6−3.4%37.6% | 4.8−35.2%49.3% | 7.4−26.4%33.7% | 10+48.3%22.8% | 6.8+0.2%9.1% | 6.8−14.5%18.0% | 7.9+29.3%20.6% | 6.1−1.5%13.0% | 6.2−26.4%13.0% | 8.4—27.3% | |
| Lease liabilities (non-current) | 0.6−12.3%4.9% | 0.7−39.7%7.1% | 1.1—5.2% | — | 0.2−67.5%0.3% | 0.7−37.9%1.9% | 1.1—3.0% | — | — | — | |
| Total liabilities | 5.2−4.5%42.5% | 5.5−35.8%56.3% | 8.5−41.8%38.9% | 15−19.7%33.3% | 18−3.5%24.6% | 19−20.2%50.4% | 24−8.8%62.0% | 26+24.9%55.5% | 21−13.7%43.8% | 24—78.2% | |
| Retained earnings | −421—−3429% | −407—−4186% | −388—−1771% | −369—−838% | −333—−449% | −312—−831% | −291—−759% | −274—−584% | −262—−551% | −241—−782% | |
| Shareholders' equity | 7.1+66.4%57.5% | 4.2−68.3%43.7% | 13−54.4%61.1% | 29−47.4%66.7% | 56+200%75.4% | 19+27.8%49.6% | 15−30.2%38.0% | 21−21.9%44.5% | 27+297%56.2% | 6.7—21.8% | |
| Total liabilities and equity | 12+26.5%100% | 9.7−55.7%100% | 22−50.2%100% | 44−40.6%100% | 74+97.3%100% | 38−2.0%100% | 38−18.3%100% | 47−1.4%100% | 48+54.0%100% | 31—100% | |
| Shares outstanding | 3.4+254%— | 1.0r15−89.7%— | 9.4+26.4%— | 7.4+28.9%— | 5.8+113%— | 2.7r41−88.3%— | 23+23.5%— | 19+9.0%— | 17+675%— | 2.2r31—— | |
| Cash-flow statement | |||||||||||
| Depreciation and amortization | — | 0.2−3.2%— | 0.2−66.1%— | 0.7+4.1%146% | 0.7−5.2%141% | 0.7+2.8%148% | 0.7+102%144% | 0.4−35.5%71.4% | 0.6−45.9%111% | 1.0—— | |
| Share-based compensation | 0.1−73.3%— | 0.5−37.1%— | 0.8−71.6%— | 2.7r2.7−28.9%535% | 3.8+103%752% | 1.9−19.0%370% | 2.3−50.3%457% | 4.6+317%921% | 1.1−26.9%221% | 1.5—— | |
| Cash from operating activities | −14—— | −19—— | −19—— | −23r−23—−4619% | −16—−3245% | −16—−3124% | −20—−4052% | −7.0—−1408% | −17—−3328% | −18—— | |
| Capital expenditure | −0.3—— | −0.0—— | −0.5—— | −0.3—−53.6% | −0.3—−62.3% | −0.0—−3.8% | −0.3—−69.8% | −0.1—−27.7% | −0.0—−7.7% | −0.1—— | |
| Cash from investing activities | −0.3−103%— | 9.8−10.7%— | 11+32.9%— | 8.3r8.3—1656% | −30−480%−6025% | 7.9+33.5%1585% | 5.9—1187% | −1.6—−326% | −11−221%−2199% | 9.1—— | |
| Debt issued | — | — | — | — | — | 1.3—265% | — | — | — | — | |
| Debt repaid | — | — | — | — | — | −1.3—−265% | — | — | — | — | |
| Shares issued | 14+50.4%— | 9.1+226%— | 2.8−58.6%— | 6.7r6.7−87.2%1345% | 53+131%10538% | 23+191%4562% | 7.8+814%1569% | 0.9—172% | — | — | |
| Cash from financing activities | 17+88.6%— | 9.1—— | −3.6−154%— | 6.7r6.7−87.7%1345% | 55+205%10954% | 18+129%3597% | 7.8−25.9%1569% | 11−71.0%2117% | 36+1261%7291% | 2.7—— | |
| Change in cash | 2.9+8404%— | 0.0—— | −12—— | −8.1−196%−1619% | 8.4−18.1%1684% | 10—2058% | −6.5−439%−1296% | 1.9−78.4%382% | 8.8—1764% | −6.6—— | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Sep 30, 2026 | Q3 FY2026to Sep 30, 2026 | Q2 FY2026to Jun 30, 2026 | Q1 FY2026to Mar 31, 2026 | Q4 FY2025to Dec 31, 2025 | Q3 FY2025to Sep 30, 2025 | Q2 FY2025to Jun 30, 2025 | Q1 FY2025to Mar 31, 2025 | Q4 FY2024to Dec 31, 2024 | Q3 FY2024to Sep 30, 2024 | Q2 FY2024to Jun 30, 2024 | Q1 FY2024to Mar 31, 2024 | Q4 FY2023to Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Research and development | 8.1+7.4%— | 1.8−5.6%— | 1.5+19.4%— | 2.3+8.0%— | 2.5*+11.5%— | 1.9−42.3%— | 1.2−56.5%— | 2.2−34.3%— | 2.2*−37.2%— | 3.3—— | 2.8—— | 3.3—— | 3.6*—— | |
| General and administrative | 6.7−4.1%— | 1.7+5.0%— | 1.3−13.9%— | 2.0−0.6%— | 1.8*−7.4%— | 1.6−5.5%— | 1.5−29.8%— | 2.0+15.3%— | 1.9*−20.8%— | 1.7—— | 2.2—— | 1.7—— | 2.4*—— | |
| Operating expenses | 15+1.9%— | 3.4−0.8%— | 2.8+0.9%— | 4.3+3.9%— | 4.3*+2.8%— | 3.5−29.9%— | 2.8−44.8%— | 4.1−17.3%— | 4.1*−30.5%— | 5.0—— | 5.0—— | 5.0—— | 6.0*—— | |
| Operating income | −15—— | −3.4—— | −2.8—— | −4.3—— | −4.3*—— | −3.5—— | −2.8—— | −4.1—— | −4.1*—— | −5.0—— | −5.0—— | −5.0—— | −6.0*—— | |
| Interest and finance income | — | — | — | — | — | — | — | — | 0.1*—— | 0.1—— | 0.1—— | 0.2—— | — | |
| Interest expense and finance costs | — | 0.3—— | 0.1—— | — | — | — | — | — | — | — | — | — | 0*—— | |
| Other non-operating income (expense) | — | −0.3−748%— | −0.0−183%— | — | 0.0*−56.3%— | 0.0−59.7%— | 0.0−87.9%— | — | 0.1*—— | 0.1—— | 0.2—— | 0.1—— | −0.2*—— | |
| Net income attributable to shareholders | −15—— | −3.8—— | −2.8—— | −4.2—— | −4.2*—— | −3.4—— | −2.7—— | −4.1—— | −4.1*—— | −4.8—— | −4.8—— | −4.9—— | −4.9*—— | |
| Earnings per share, basic | — | -0.64—— | -0.54—— | -0.84—— | — | -1.16—— | -2.15—— | -3.15r-0.28—— | — | -3.76r-0.34—— | -7.64r-0.51—— | -0.52—— | — | |
| Earnings per share, diluted | — | -0.64—— | -0.54—— | -0.84—— | — | -1.16—— | -2.15—— | -3.15r-0.28—— | — | -3.76r-0.34—— | -7.64r-0.51—— | -0.52—— | — | |
| Shares, weighted average (basic) | 5.9+102%— | 5.9+102%— | 5.2+310%— | 5.0+287%— | — | 2.9+128%— | 1.3+104%— | 1.3r15−86.2%— | — | 1.3r14—— | 0.6r9.4—— | 9.4—— | — | |
| Shares, weighted average (diluted) | 5.9+102%— | 5.9+102%— | 5.2+310%— | 5.0+287%— | — | 2.9+128%— | 1.3+104%— | 1.3r15−86.2%— | — | 1.3r14—— | 0.6r9.4—— | 9.4—— | — | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 4.0—33.6% | 4.0−23.1%33.6% | 6.9+45.2%45.8% | 4.8+66.9%59.8% | 8.8+49.5%71.5% | 5.3−49.1%58.4% | 4.7−10.9%53.8% | 2.9+22.4%41.8% | 5.9+0.6%60.4% | 10—71.7% | 5.3—54.8% | 2.3—16.4% | 5.8—26.6% | |
| Short-term investments | — | — | — | — | — | — | — | — | — | — | — | 7.5—52.1% | 9.8—44.7% | |
| Current assets | 5.8—48.6% | 5.8−19.6%48.6% | 8.7+26.1%58.0% | 6.6+30.0%82.6% | 11+33.9%87.3% | 7.3−42.1%80.8% | 6.9−9.9%78.4% | 5.1−57.9%74.2% | 8.0−56.1%82.4% | 13—87.1% | 7.6—78.9% | 12—84.4% | 18—83.2% | |
| Property, plant and equipment | 0.4—3.3% | 0.4−34.5%3.3% | 0.5−32.2%3.1% | 0.5−37.4%5.7% | 0.5−2.1%4.3% | 0.6+6.7%6.7% | 0.7+8.2%7.7% | 0.7+5.9%10.7% | 0.5−28.0%5.6% | 0.6—3.9% | 0.6—6.4% | 0.7—4.8% | 0.8—3.4% | |
| Right-of-use (leased) assets | 0.7—5.7% | 0.7−36.3%5.7% | 0.8−32.6%5.3% | 0.9−9.9%11.1% | 1.0−11.9%8.0% | 1.1−13.4%12.0% | 1.2−14.6%13.3% | 1.0−33.7%14.4% | 1.1−30.0%11.5% | 1.2—8.7% | 1.4—14.1% | 1.5—10.4% | 1.6—7.3% | |
| Total assets | 12—100% | 12+33.6%100% | 15+70.6%100% | 8.0+16.9%100% | 12+26.5%100% | 9.0−37.5%100% | 8.8−9.3%100% | 6.9−52.1%100% | 9.7−55.7%100% | 14—100% | 9.7—100% | 14—100% | 22—100% | |
| Accounts payable | 1.3—10.6% | 1.3+13.3%10.6% | 1.6−6.7%10.8% | 1.0−48.1%12.0% | 1.4+7.1%11.3% | 1.1−52.3%12.5% | 1.7−11.9%19.7% | 1.9−21.2%27.1% | 1.3−63.0%13.4% | 2.4—16.4% | 2.0—20.3% | 2.4—16.5% | 3.5—16.0% | |
| Current liabilities | 4.2—35.3% | 4.2+1.0%35.3% | 4.8−10.1%31.9% | 4.2−28.1%52.0% | 4.6−3.4%37.6% | 4.2−22.9%46.7% | 5.3+4.7%60.5% | 5.8+20.3%84.5% | 4.8−35.2%49.3% | 5.4—37.8% | 5.1—52.4% | 4.8—33.6% | 7.4—33.7% | |
| Lease liabilities (non-current) | 0.3—2.2% | 0.3−62.8%2.2% | 0.4−53.2%2.5% | 0.5−19.6%6.1% | 0.6−12.3%4.9% | 0.7−6.5%7.9% | 0.8−7.1%9.2% | 0.6−39.2%8.9% | 0.7−39.7%7.1% | 0.8—5.3% | 0.9—9.0% | 1.0—7.0% | 1.1—5.2% | |
| Total liabilities | 9.4—78.2% | 9.4+91.3%78.2% | 11+76.2%72.1% | 4.7−27.3%58.1% | 5.2−4.5%42.5% | 4.9−20.9%54.6% | 6.1+3.0%69.7% | 6.4+10.0%93.4% | 5.5−35.8%56.3% | 6.2—43.1% | 6.0—61.4% | 5.8—40.7% | 8.5—38.9% | |
| Retained earnings | −432—−3598% | −432—−3598% | −428—−2858% | −426—−5307% | −421—−3429% | −417—−4640% | −414—−4707% | −411—−5988% | −407—−4186% | −403—−2799% | −398—−4106% | −393—−2744% | −388—−1771% | |
| Shareholders' equity | 2.6—21.8% | 2.6−35.8%21.8% | 4.2+57.5%27.9% | 3.4+643%41.9% | 7.1+66.4%57.5% | 4.1−50.2%45.4% | 2.7−28.9%30.3% | 0.5−94.7%6.6% | 4.2−68.3%43.7% | 8.2—56.9% | 3.7—38.6% | 8.5—59.3% | 13—61.1% | |
| Total liabilities and equity | 12—100% | 12+33.6%100% | 15+70.6%100% | 8.0+16.9%100% | 12+26.5%100% | 9.0−37.5%100% | 8.8−9.3%100% | 6.9−52.1%100% | 9.7−55.7%100% | 14—100% | 9.7—100% | 14—100% | 22—100% | |
| Shares outstanding | 6.2—— | 6.2+114%— | 4.7+172%— | 3.9−73.2%— | 3.4+254%— | 2.9−80.0%— | 1.7−81.7%— | 15+55.5%— | 1.0r15−89.7%— | 15—— | 9.4—— | 9.4—— | 9.4—— | |
| Cash-flow statement | ||||||||||||||
| Share-based compensation | 0.7—— | 0.1*—— | 0.1*−23.9%— | 0.5+168%— | 0.0*−89.8%— | — | 0.1*−24.6%— | 0.2—— | 0.1*−15.2%— | 0.2*—— | 0.2*—— | −0.0—— | 0.1*—— | |
| Cash from operating activities | −14—— | −3.2*—— | −3.0*—— | −4.0—— | −3.7*—— | −4.4*—— | −3.0*—— | −2.8—— | −4.4*—— | −4.1*—— | −4.5*—— | −5.9—— | −3.8*—— | |
| Capital expenditure | — | −0.0*—— | — | — | −0.0*—— | 0*—— | −0.0*—— | −0.3—— | −0.0*—— | −0.0*—— | 0*—— | −0.0—— | 0*—— | |
| Cash from investing activities | — | −0.0*—— | — | — | −0.0*—— | 0*—— | −0.0*−100%— | −0.3−111%— | −0.0*—— | −0.0*—— | 7.5*—— | 2.4—— | −3.3*—— | |
| Shares issued | — | 0.5*−87.0%— | — | — | 7.2*—— | 3.5*—— | 2.9*—— | 0.1—— | −0.0*−111%— | — | — | — | 0.0*—— | |
| Cash from financing activities | 18+79.7%— | 0.4*−91.6%— | 10*+111%— | −0.0−102%— | 7.2*—— | 5.0*—— | 4.8*—— | 0.1—— | −0.0*−111%— | — | — | — | 0.0*—— | |
| Change in cash | 3.8—— | −2.8*−633%— | 7.1*+281%— | −4.0—— | 3.5*—— | 0.5*−89.6%— | 1.9*−37.3%— | −3.0—— | −4.4*—— | 5.0*—— | 3.0*—— | −3.5—— | −7.0*—— | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
Executive pay at Imunon, Inc.#
From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.
| Fiscal year | CEO total pay | Actually paid | Other executives, average | $100 invested |
|---|---|---|---|---|
| 2025Dr. Lindborg | $1.0 M | $751 K | $598 K | $18 |
| 2024Stacy Lindborg | $1.2 M | $1.1 M | $567 K | $63 |
| 2023Dr. Le Goff | $1.1 M | $911 K | $680 K | $45 |
Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025
Events at Imunon, Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
Warning signs in the last three years
Delisting notice 3 · Directors and officers 8 · Material agreement 5 · New debt 1 · Unregistered share sale 3 · Shareholder rights changed 2 · Bylaws or fiscal year changed 4 · Shareholder vote 2 · Results announced 6
| Filed | What happened | Filing |
|---|---|---|
| Results announced | 8-K | |
| Material agreement | 8-K | |
| Material agreementUnregistered share saleBylaws or fiscal year changed | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Directors and officers | 8-K | |
| Directors and officersShareholder vote | 8-K | |
| Material agreementNew debtUnregistered share saleBylaws or fiscal year changed | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Directors and officers | 8-K | |
| Material agreement | 8-K | |
| Results announced | 8-K | |
| Delisting notice | 8-K | |
| Results announced | 8-K | |
| Shareholder rights changedBylaws or fiscal year changed | 8-K | |
| Delisting noticeDirectors and officers | 8-K | |
| Shareholder rights changedBylaws or fiscal year changedShareholder vote | 8-K | |
| Directors and officers | 8-K | |
| Delisting notice | 8-K | |
| Material agreementUnregistered share sale | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Nov 12, 2026
Acquisitions and funding#
1 private funding rounds before listing
Private share sales · funding history
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| May 2025 | $3 M | Private placement after listing | $2 to $10 million | 3 | equity, options | SEC |
| Aug 2024 | $10 M | Private placement after listing | $10 to $50 million | 4 | equity, options | SEC |
| Jun 2015 | $5 M | Private placement after listing | $2 to $10 million | 3 | options | SEC |
| Jun 2014 | $9 M | Private placement after listing | $2 to $10 million | 1 | equity | SEC |
| Jun 2011 | $9 M | No. 1 | $2 to $10 million | 31 | equity | SEC |
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
How Imunon, Inc. compares in Biotechnology
- Market cap$5 M · higher than 6% of 726
- Revenue growth0.0% · higher than 42% of 438
- Price / book0.8× · lower than 83% of 534
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Imunon, Inc.🇺🇸 | $5 M | — | — | 0.0% |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Regenxbio Inc.$513 M
- Pharmicell Co., Ltd.$514 M
- Pulike Biological Engineering, Inc.$524 M
- Contineum Therapeutics, Inc.$534 M
- Entera Bio Ltd.$543 M
- Arvinas, Inc.$544 M
Sources and freshness
- Market cap:
- Oct 30, 2026
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Employees:
- As of March 30, 2026
- Profile updated:
- Nov 19, 2026
Figures from Market data, SEC filing, value.today research, SEC annual report, GLEIF register; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Imunon, Inc.? Verify and update this profile — free
Show Imunon, Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.